Precision Solutions

• 
  Mechanism of USP8 Regulating MDA5 Homeostasis and Its Therapeutic Potential in Autoimmune Diseases

  This study identifies USP8 as the key deubiquitinase regulating MDA5 homeostasis and reveals the AKT-USP8-MDA5 axis. AKT phosphorylates USP8 at Ser718, enhancing its activity and stabilizing MDA5 to promote type I interferon signaling. Targeting this axis offers a potential therapeutic strategy for MDA5-associated autoimmune diseases.

• 
  Simvastatin Reverses Ferroptosis and Chemo-Immunotherapy Resistance in AKT-Hyperactivated Intrahepatic Cholangiocarcinoma by Targeting the pPCK1-pLDHA-SPRINGlac Axis

  Intrahepatic cholangiocarcinoma (ICC) has poor prognosis due to chemo-immunotherapy (CIT) resistance, especially in AKT-hyperactivated cases. Published in Cancer Communications (2025), this study identified the pAKT-pPCK1-pLDHA-SPRINGlac axis as a key resistance driver. AtaGenix’s phospho-specific antibodies enabled core detection, and simvastatin reversed resistance by targeting the axis, with pAKT-pPCK1 as a prognostic biomarker.

• 
  Deciphering PAD1-Mediated Regulation of Ovarian Cancer Stem Cells with AtaGenix-Customized Antibody

  This study identifies the PAD1-AKT2/R202 citrullination-CEBPβ axis as a key regulator of ovarian cancer stem cell (OCSC) properties and cisplatin resistance. Using an AtaGenix-customized Cit202 antibody, it demonstrates that PAD1-mediated citrullination activates AKT2, promoting stemness and resistance, which can be targeted with PAD1 inhibitor combined with cisplatin.